Selected research
Industry Research
Oral Voriconazole Industry Research Report 2026
Market perspective
The global Oral Voriconazole market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Oral Voriconazole market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Oral Voriconazole market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Oral Voriconazole market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Oral Voriconazole include Zhuhai Rundu Pharmaceutical, Yangzijiang Pharmaceutical Group, Poly Pharm, Union-Bio science, Huahai Pharmaceutical, Brilliant Pharmaceuticals, Beijing Genetech Pharmaceutical, Viona Pharmaceuticals and Teva, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Oral Voriconazole market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Oral Voriconazole.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Oral Voriconazole Market by Company
Zhuhai Rundu Pharmaceutical
Yangzijiang Pharmaceutical Group
Poly Pharm
Union-Bio science
Huahai Pharmaceutical
Brilliant Pharmaceuticals
Beijing Genetech Pharmaceutical
Viona Pharmaceuticals
Teva
Taj Pharmaceuticals
Sun Pharmaceutical
SiNi Pharma
Sandoz
Pfizer
Lupin Pharmaceuticals
Oral Voriconazole Segment by Type
Voriconazole Suspension
Voriconazole Capsules
Voriconazole Tablets
Oral Voriconazole Segment by Application
Hospital Pharmacy
Retail Pharmacy
Oral Voriconazole Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Voriconazole market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oral Voriconazole and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Voriconazole.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Oral Voriconazole companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Voriconazole Suspension
- Voriconazole Capsules
- Voriconazole Tablets
Applications
- Hospital Pharmacy
- Retail Pharmacy
Companies covered
- Zhuhai Rundu Pharmaceutical
- Yangzijiang Pharmaceutical Group
- Poly Pharm
- Union-Bio science
- Huahai Pharmaceutical
- Brilliant Pharmaceuticals
- Beijing Genetech Pharmaceutical
- Viona Pharmaceuticals
- Teva
- Taj Pharmaceuticals
- Sun Pharmaceutical
- SiNi Pharma
- Sandoz
- Pfizer
- Lupin Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Oral Voriconazole by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Voriconazole Suspension
- 2.2.3 Voriconazole Capsules
- 2.2.4 Voriconazole Tablets
- 2.3 Oral Voriconazole by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital Pharmacy
- 2.3.3 Retail Pharmacy
- 2.4 Assumptions and Limitations
3 Oral Voriconazole Breakdown Data by Type
- 3.1 Global Oral Voriconazole Historic Market Size by Type (2021-2026)
- 3.2 Global Oral Voriconazole Forecasted Market Size by Type (2027-2032)
4 Oral Voriconazole Breakdown Data by Application
- 4.1 Global Oral Voriconazole Historic Market Size by Application (2021-2026)
- 4.2 Global Oral Voriconazole Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Oral Voriconazole Market Perspective (2021-2032)
- 5.2 Global Oral Voriconazole Growth Trends by Region
- 5.2.1 Global Oral Voriconazole Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Oral Voriconazole Historic Market Size by Region (2021-2026)
- 5.2.3 Oral Voriconazole Forecasted Market Size by Region (2027-2032)
- 5.3 Oral Voriconazole Market Dynamics
- 5.3.1 Oral Voriconazole Industry Trends
- 5.3.2 Oral Voriconazole Market Drivers
- 5.3.3 Oral Voriconazole Market Challenges
- 5.3.4 Oral Voriconazole Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Oral Voriconazole Players by Revenue
- 6.1.1 Global Top Oral Voriconazole Players by Revenue (2021-2026)
- 6.1.2 Global Oral Voriconazole Revenue Market Share by Players (2021-2026)
- 6.2 Global Oral Voriconazole Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Oral Voriconazole Head Office and Area Served
- 6.4 Global Oral Voriconazole Players, Product Type & Application
- 6.5 Global Oral Voriconazole Manufacturers Established Date
- 6.6 Global Oral Voriconazole Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Oral Voriconazole Market Size (2021-2032)
- 7.2 North America Oral Voriconazole Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Oral Voriconazole Market Size by Country (2021-2026)
- 7.4 North America Oral Voriconazole Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Oral Voriconazole Market Size (2021-2032)
- 8.2 Europe Oral Voriconazole Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Oral Voriconazole Market Size by Country (2021-2026)
- 8.4 Europe Oral Voriconazole Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Oral Voriconazole Market Size (2021-2032)
- 9.2 Asia-Pacific Oral Voriconazole Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Oral Voriconazole Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Oral Voriconazole Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Oral Voriconazole Market Size (2021-2032)
- 10.2 South America Oral Voriconazole Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Oral Voriconazole Market Size by Country (2021-2026)
- 10.4 South America Oral Voriconazole Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Oral Voriconazole Market Size (2021-2032)
- 11.2 Middle East & Africa Oral Voriconazole Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Oral Voriconazole Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Oral Voriconazole Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Zhuhai Rundu Pharmaceutical
- 12.1.1 Zhuhai Rundu Pharmaceutical Company Information
- 12.1.2 Zhuhai Rundu Pharmaceutical Business Overview
- 12.1.3 Zhuhai Rundu Pharmaceutical Revenue in Oral Voriconazole Business (2021-2026)
- 12.1.4 Zhuhai Rundu Pharmaceutical Oral Voriconazole Product Portfolio
- 12.1.5 Zhuhai Rundu Pharmaceutical Recent Developments
- 12.2 Yangzijiang Pharmaceutical Group
- 12.2.1 Yangzijiang Pharmaceutical Group Company Information
- 12.2.2 Yangzijiang Pharmaceutical Group Business Overview
- 12.2.3 Yangzijiang Pharmaceutical Group Revenue in Oral Voriconazole Business (2021-2026)
- 12.2.4 Yangzijiang Pharmaceutical Group Oral Voriconazole Product Portfolio
- 12.2.5 Yangzijiang Pharmaceutical Group Recent Developments
- 12.3 Poly Pharm
- 12.3.1 Poly Pharm Company Information
- 12.3.2 Poly Pharm Business Overview
- 12.3.3 Poly Pharm Revenue in Oral Voriconazole Business (2021-2026)
- 12.3.4 Poly Pharm Oral Voriconazole Product Portfolio
- 12.3.5 Poly Pharm Recent Developments
- 12.4 Union-Bio science
- 12.4.1 Union-Bio science Company Information
- 12.4.2 Union-Bio science Business Overview
- 12.4.3 Union-Bio science Revenue in Oral Voriconazole Business (2021-2026)
- 12.4.4 Union-Bio science Oral Voriconazole Product Portfolio
- 12.4.5 Union-Bio science Recent Developments
- 12.5 Huahai Pharmaceutical
- 12.5.1 Huahai Pharmaceutical Company Information
- 12.5.2 Huahai Pharmaceutical Business Overview
- 12.5.3 Huahai Pharmaceutical Revenue in Oral Voriconazole Business (2021-2026)
- 12.5.4 Huahai Pharmaceutical Oral Voriconazole Product Portfolio
- 12.5.5 Huahai Pharmaceutical Recent Developments
- 12.6 Brilliant Pharmaceuticals
- 12.6.1 Brilliant Pharmaceuticals Company Information
- 12.6.2 Brilliant Pharmaceuticals Business Overview
- 12.6.3 Brilliant Pharmaceuticals Revenue in Oral Voriconazole Business (2021-2026)
- 12.6.4 Brilliant Pharmaceuticals Oral Voriconazole Product Portfolio
- 12.6.5 Brilliant Pharmaceuticals Recent Developments
- 12.7 Beijing Genetech Pharmaceutical
- 12.7.1 Beijing Genetech Pharmaceutical Company Information
- 12.7.2 Beijing Genetech Pharmaceutical Business Overview
- 12.7.3 Beijing Genetech Pharmaceutical Revenue in Oral Voriconazole Business (2021-2026)
- 12.7.4 Beijing Genetech Pharmaceutical Oral Voriconazole Product Portfolio
- 12.7.5 Beijing Genetech Pharmaceutical Recent Developments
- 12.8 Viona Pharmaceuticals
- 12.8.1 Viona Pharmaceuticals Company Information
- 12.8.2 Viona Pharmaceuticals Business Overview
- 12.8.3 Viona Pharmaceuticals Revenue in Oral Voriconazole Business (2021-2026)
- 12.8.4 Viona Pharmaceuticals Oral Voriconazole Product Portfolio
- 12.8.5 Viona Pharmaceuticals Recent Developments
- 12.9 Teva
- 12.9.1 Teva Company Information
- 12.9.2 Teva Business Overview
- 12.9.3 Teva Revenue in Oral Voriconazole Business (2021-2026)
- 12.9.4 Teva Oral Voriconazole Product Portfolio
- 12.9.5 Teva Recent Developments
- 12.10 Taj Pharmaceuticals
- 12.10.1 Taj Pharmaceuticals Company Information
- 12.10.2 Taj Pharmaceuticals Business Overview
- 12.10.3 Taj Pharmaceuticals Revenue in Oral Voriconazole Business (2021-2026)
- 12.10.4 Taj Pharmaceuticals Oral Voriconazole Product Portfolio
- 12.10.5 Taj Pharmaceuticals Recent Developments
- 12.11 Sun Pharmaceutical
- 12.11.1 Sun Pharmaceutical Company Information
- 12.11.2 Sun Pharmaceutical Business Overview
- 12.11.3 Sun Pharmaceutical Revenue in Oral Voriconazole Business (2021-2026)
- 12.11.4 Sun Pharmaceutical Oral Voriconazole Product Portfolio
- 12.11.5 Sun Pharmaceutical Recent Developments
- 12.12 SiNi Pharma
- 12.12.1 SiNi Pharma Company Information
- 12.12.2 SiNi Pharma Business Overview
- 12.12.3 SiNi Pharma Revenue in Oral Voriconazole Business (2021-2026)
- 12.12.4 SiNi Pharma Oral Voriconazole Product Portfolio
- 12.12.5 SiNi Pharma Recent Developments
- 12.13 Sandoz
- 12.13.1 Sandoz Company Information
- 12.13.2 Sandoz Business Overview
- 12.13.3 Sandoz Revenue in Oral Voriconazole Business (2021-2026)
- 12.13.4 Sandoz Oral Voriconazole Product Portfolio
- 12.13.5 Sandoz Recent Developments
- 12.14 Pfizer
- 12.14.1 Pfizer Company Information
- 12.14.2 Pfizer Business Overview
- 12.14.3 Pfizer Revenue in Oral Voriconazole Business (2021-2026)
- 12.14.4 Pfizer Oral Voriconazole Product Portfolio
- 12.14.5 Pfizer Recent Developments
- 12.15 Lupin Pharmaceuticals
- 12.15.1 Lupin Pharmaceuticals Company Information
- 12.15.2 Lupin Pharmaceuticals Business Overview
- 12.15.3 Lupin Pharmaceuticals Revenue in Oral Voriconazole Business (2021-2026)
- 12.15.4 Lupin Pharmaceuticals Oral Voriconazole Product Portfolio
- 12.15.5 Lupin Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst